Arvinas Inc.
ARVN · United States
Share price · ARVN
Loading chart…
Prices are end-of-day (EOD), delayed by 24 hours · Adjusted for stock splits · Data via Databento
Unusual price moves
Days when ARVN's shares moved far more than they usually do, with what was announced that day or the session before. An announcement on the same day does not show that it caused the move. How the days are picked
- 5 Nov 2026-11.7%
- 3 Nov 2026-5.7%
- 13 Oct 2026-8.2%
Nothing announced by ARVN that day or the session before.
- 5 Aug 2026-6.7%
- 4 Aug 2026+11.7%
- 12 Jun 2026+6.9%
Nothing announced by ARVN that day or the session before.
- 1 May 2026+6.2%
- 1 Apr 2026+6.9%
Nothing announced by ARVN that day or the session before.
- 23 Mar 2026-5.7%
Nothing announced by ARVN that day or the session before.
- 18 Mar 2026-9.3%
Share of unusual movement by asset
For each asset, the share of ARVN's own-move activity since 2 Jul 2024 that fell on the session of one of the asset's own announcements or the session after it. Large moves count for much more than small ones. A session shared by several assets is split between them. A share is shown once an asset has at least 8 event days; below that, its events are listed instead.
Assets
(4 total)
| Target & Modality | |||
|---|---|---|---|
Vepdegestrant(Veppanu) | Approved | Estrogen receptorSmall molecule | Breast Cancer HR+/HER2- Metastatic Breast Cancer |
| Phase 2 | Androgen receptor · Androgen receptor (degrader)Small molecule | Metastatic Castration-Resistant Prostate Cancer | |
| Phase 1/2 | KRAS G12DSmall molecule | Non-Small Cell Lung CancerPancreatic Ductal Adenocarcinoma | |
| Phase 1 | LRRK2Small molecule | Parkinson's Disease |
Upcoming events
(7 total)
Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.
2026 (2)
2027 (3)
2029 (2)
August 2029 (1)
What to watch
November 2029 (1)
What to watch
Regulatory and conference events
(3)
Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.
Recent
Financial reports
Quarterly & interim (16)
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2026-Q3 | $0.5M | $47M | $89M+ $470M short-term inv. | $54M-$10M operating cash flow | report ↗ |
View 15 more
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2026-Q2 | — | $53M | $94M+ $474M short-term inv. | —-$48M operating cash flow | report ↗ |
| 2026-Q1 | — | $60M | $87M+ $528M short-term inv. | $58M-$69M operating cash flow | report ↗ |
| 2025-Q3 | $42M | $65M | $102M+ $686M short-term inv. | $35M-$59M operating cash flow | report ↗ |
| 2025-Q2 | $22M | $69M | $115M+ $746M short-term inv. | $61M-$95M operating cash flow | report ↗ |
| 2025-Q1 | $189M | $91M | $81M+ $873M short-term inv. | —-$89M operating cash flow | report ↗ |
| 2024-Q3 | $102M | $87M | $85M+ $1.0B short-term inv. | $49M-$128M operating cash flow | report ↗ |
| 2024-Q2 | $77M | $94M | $160M+ $1.1B short-term inv. | $35M$50M operating cash flow | report ↗ |
| 2024-Q1 | $25M | $84M | $94M+ $1.1B short-term inv. | $69M-$98M operating cash flow | report ↗ |
| 2023-Q3 | $35M | $86M | $119M+ $885M short-term inv. | $64M-$85M operating cash flow | report ↗ |
| 2023-Q2 | $55M | $103M | $96M+ $948M short-term inv. | $67M-$89M operating cash flow | report ↗ |
| 2023-Q1 | $33M | $95M | $136M+ $993M short-term inv. | $82M-$91M operating cash flow | report ↗ |
| 2022-Q3 | $30M | $78M | $138M+ $1.1B short-term inv. | $66M-$67M operating cash flow | report ↗ |
| 2022-Q2 | $31M | $75M | $98M+ $1.3B short-term inv. | $70M-$79M operating cash flow | report ↗ |
| 2022-Q1 | $24M | $64M | $67M+ $1.4B short-term inv. | $63M-$57M operating cash flow | report ↗ |
| 2021-Q3 | $9.3M | $41M | $260M+ $1.3B short-term inv. | $47M$682M operating cash flow | report ↗ |
Annual history (5 years)
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2025-FY | $263M | $285M | $143M+ $543M short-term inv. | $20M-$274M operating cash flow | report ↗ |
For full-year 2025, Arvinas reported revenue of $262.6M, down 0.3% YoY, and R&D expenses of $285.2M, down 18.1% YoY. Cash and equivalents were $142.9M, with a net loss of -$80.8M for the year and a quarterly net burn of $80.8M.
Management guided that cash, cash equivalents, and marketable securities as of December 31, 2025 are sufficient to fund operations into the second half of 2028. Pipeline updates included oral presentation of ARV-102 Phase 1 data at AD/PD in March 2026, initial ARV-806 clinical data expected in 2026, continued ARV-393 dose escalation with a planned glofitamab combination cohort, initiation of a first-in-human Phase 1 trial for ARV-027, and ARV-6723 on track for Phase 1 initiation in mid-2026. The company also highlighted the vepdegestrant PDUFA action date of June 5, 2026, plans to select a commercialization partner for vepdegestrant, and the appointment of Randy Teel, Ph.D., as President and CEO.
View 4 more years
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2024-FY | $263M | $348M | $101M+ $939M short-term inv. | $50M-$259M operating cash flow | report ↗ |
| 2023-FY | $79M | $380M | $317M+ $949M short-term inv. | $92M-$348M operating cash flow | report ↗ |
| 2022-FY | $131M | $315M | $87M+ $1.1B short-term inv. | $71M-$274M operating cash flow | report ↗ |
| 2021-FY | $47M | $180M | $113M+ $1.4B short-term inv. | $48M$559M operating cash flow | report ↗ |
Insider transactions
Open-market activity, trailing 12 months: 1 purchase ($268K), 23 sales ($1.4M). Awards, option exercises and tax-withholding rows are listed below but excluded from these totals.
| Source | ||||||
|---|---|---|---|---|---|---|
| 2026-11-09 | Loomis David K · VP, Chief Accounting Officer | Open-market sale | 232 | $6.36 | $1K | Form 4 |
| 2026-06-24 | Bain Linda · director | Award / grant | 15,527 | — | — | Form 4 |
| 2026-06-24 | Cunningham Everett · director | Award / grant | 15,527 | — | — | Form 4 |
| 2026-06-24 | Kennedy Edward Moore Jr. · director | Award / grant | 15,527 | — | — | Form 4 |
| 2026-06-24 | Morrison Briggs · director | Award / grant | 15,527 | — | — | Form 4 |
| 2026-06-24 | Norwalk Leslie V · director | Award / grant | 15,527 | — | — | Form 4 |
| 2026-06-24 | Smaldone Alsup Laurie · director | Award / grant | 15,527 | — | — | Form 4 |
| 2026-06-24 | Bain Linda · director | Award / grant (derivative) | 22,714 | — | — | Form 4 |
Institutional holders
From SEC Form 13F filings for the quarter ended 2026-03-31 (filed up to 45 days later). 206 reporting institutions held 54.1M shares ($550.1M, 82.6% of shares outstanding).
| # | Institution | Shares | Value |
|---|---|---|---|
| 1 | BlackRock, Inc. | 6,797,584 | $72.1M |
| 2 | VANGUARD PORTFOLIO MANAGEMENT LLC | 3,889,628 | $41.2M |
| 3 | D. E. Shaw & Co., Inc. | 3,638,567 | $38.6M |
| 4 | Pfizer Inc | 3,457,815 | $34.9M |
| 5 | VANGUARD CAPITAL MANAGEMENT LLC | 2,689,362 | $28.5M |
| 6 | TCG Crossover Management, LLC | 2,387,461 | $25.3M |
| 7 | ARMISTICE CAPITAL, LLC | 1,978,000 | $21.0M |
| 8 | TWO SIGMA INVESTMENTS, LP | 1,832,114 | $19.4M |
| 9 | STATE STREET CORP | 1,828,472 | $19.4M |
| 10 | GEODE CAPITAL MANAGEMENT, LLC | 1,557,107 | $16.5M |
| 11 | JACOBS LEVY EQUITY MANAGEMENT, INC | 1,441,521 | $15.3M |
| 12 | Qube Research & Technologies Ltd | 1,201,635 | $12.7M |
| 13 | CITADEL ADVISORS LLC | 1,180,988 | $12.5M |
| 14 | FEDERATED HERMES, INC. | 1,140,715 | $12.1M |
| 15 | Vestal Point Capital, LP | 905,465 | $9.6M |